Phenotypic screening in cancer drug discovery — past, present and future
The DOI matches its Crossref record; 181 of the 182 references it cites were found in a registry or an index.
Abstract
There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches. Given that oncology is currently the most active therapeutic area, and also one in which target-focused approaches have been particularly prominent in the past two decades, we investigated the contribution of phenotypic assays to oncology drug discovery by analysing the origins of all new small-molecule cancer drugs approved by the US Food and Drug Administration (FDA) over the past 15 years and those currently in clinical development. Although the majority of these drugs originated from target-based discovery, we identified a significant number whose discovery depended on phenotypic screening approaches. We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes. However, technical and biological advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Phenotypic screening is a strategy that analyzes biology-associated (phenotypic) effects in given models such as animals, cells, or organisms to help identify the targets of candidate drugs.25,50”
From Drug repurposing for cancer therapy (2024) · cites this paper as [25]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
A History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970
Believe it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Spheroid-based drug screen: Considerations and practical approach
Friedrich, J., Seidel, C., Ebner, R., & Kunz-Schughart, L. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.226 · Cited by 1,742
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Sottoriva, A., Spiteri, I., Piccirillo, S. G. M., Touloumis, A., Collins, V. P., Marioni, J. C., Curtis, C., Watts, C., & Tavaré, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219747110 · Cited by 1,737
Small Molecule Inhibitor of Mitotic Spindle Bipolarity Identified in a Phenotype-Based Screen
Mayer, T. U., Kapoor, T. M., Haggarty, S. J., King, R. W., Schreiber, S. L., & Mitchison, T. J. (1999) · Science · doi:10.1126/science.286.5441.971 · Cited by 1,727
RAS–RAF–MEK-dependent oxidative cell death involving voltage-dependent anion channels
Yagoda, N., von Rechenberg, M., Zaganjor, E., Bauer, A. J., Yang, W. S., Fridman, D. J., Wolpaw, A. J., Smukste, I., Peltier, J. M., Boniface, J. J., et al. (2007) · Nature · doi:10.1038/nature05859 · Cited by 1,631
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Dolma, S., Lessnick, S. L., Hahn, W. C., & Stockwell, B. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00050-3 · Cited by 1,446
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
Small molecule–mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer
Chen, B., Dodge, M. E., Tang, W., Lu, J., Ma, Z., Fan, C.-W., Wei, S., Hao, W., Kilgore, J., Williams, N. S., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.137 · Cited by 1,383
Friend, C., Scher, W., Holland, J. G., & Sato, T. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.2.378 · Cited by 1,352
Epigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
Lessons from the Cancer Genome
Garraway, L. A., & Lander, E. S. (2013) · Cell · doi:10.1016/j.cell.2013.03.002 · Cited by 1,308
Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
Cancer Stem Cells: Current Status and Evolving Complexities
Visvader, J. E., & Lindeman, G. J. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.007 · Cited by 1,287
Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 932
BindingDB (2025) · PubMed · doi:10.7270/q2dr317m · Cited by 843
Quintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843
Vemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 757
Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma
Snuderl, M., Fazlollahi, L., Le, L. P., Nitta, M., Zhelyazkova, B. H., Davidson, C. J., Akhavanfard, S., Cahill, D. P., Aldape, K. D., Betensky, R. A., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.005 · Cited by 707
Cancer stem cell definitions and terminology: the devil is in the details
Valent, P., Bonnet, D., De Maria, R., Lapidot, T., Copland, M., Melo, J. V., Chomienne, C., Ishikawa, F., Schuringa, J. J., Stassi, G., et al. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3368 · Cited by 692
Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4086 · Cited by 678
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
The outgrowth of the nerve fiber as a mode of protoplasmic movement
Harrison, R. G. (1910) · Journal of Experimental Zoology · doi:10.1002/jez.1400090405 · Cited by 642
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 587
Korff, T., & Augustin, H. G. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.5.1341 · Cited by 559
Target-based drug discovery: is something wrong?
Sams-Dodd, F. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03316-1 · Cited by 522
Sun, L., Liang, C., Shirazian, S., Zhou, Y., Miller, T., Cui, J., Fukuda, J. Y., Chu, J.-Y., Nematalla, A., Wang, X., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0204183 · Cited by 521
The proteasome inhibitor PS-341 in cancer therapy.
Teicher, B. A., Ara, G., Herbst, R. S., Palombella, V. J., & Adams, J. (1999) · PubMed · Cited by 521
Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells?
Takahashi-Yanaga, F., & Kahn, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2943 · Cited by 499
Nakahara, T., Takeuchi, M., Kinoyama, I., Minematsu, T., Shirasuna, K., Matsuhisa, A., Kita, A., Tominaga, F., Yamanaka, K., Kudoh, M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1343 · Cited by 497
Jordan, M. A., Kamath, K., Manna, T., Okouneva, T., Miller, H. P., Davis, C., Littlefield, B. A., & Wilson, L. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0345 · Cited by 489
UEDA, H., NAKAJIMA, H., HORI, Y., FUJITA, T., NISHIMURA, M., GOTO, T., & OKUHARA, M. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.301 · Cited by 489
FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor
Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., & Horinouchi, S. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4027 · Cited by 487
Small molecule regulators of autophagy identified by an image-based high-throughput screen
Zhang, L., Yu, J., Pan, H., Hu, P., Hao, Y., Cai, W., Zhu, H., Yu, A. D., Xie, X., Ma, D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709695104 · Cited by 470
Mechanism of action of lenalidomide in hematological malignancies
Kotla, V., Goel, S., Nischal, S., Heuck, C., Vivek, K., Das, B., & Verma, A. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-36 · Cited by 467
The outgrowth of the nerve fiber as a mode of protoplasmic movement
Harrison, R. G. (1959) · Journal of Experimental Zoology · doi:10.1002/jez.1401420103 · Cited by 455
Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines
Swinney, D. C. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.236 · Cited by 413
GDC-0449—A potent inhibitor of the hedgehog pathway
Robarge, K. D., Brunton, S. A., Castanedo, G. M., Cui, Y., Dina, M. S., Goldsmith, R., Gould, S. E., Guichert, O., Gunzner, J. L., Halladay, J., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.049 · Cited by 386
O'Donnell, A., Judson, I., Dowsett, M., Raynaud, F., Dearnaley, D., Mason, M., Harland, S., Robbins, A., Halbert, G., Nutley, B., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601879 · Cited by 382
Potter, G. A., Barrie, S. E., Jarman, M., & Rowlands, M. G. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00013a022 · Cited by 379
Puttini, M., Coluccia, A. M. L., Boschelli, F., Cleris, L., Marchesi, E., Donella-Deana, A., Ahmed, S., Redaelli, S., Piazza, R., Magistroni, V., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1199 · Cited by 375
Huang, W.-S., Metcalf, C. A., Sundaramoorthi, R., Wang, Y., Zou, D., Thomas, R. M., Zhu, X., Cai, L., Wen, D., Liu, S., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100395q · Cited by 369
Leoni, L. M., Bailey, B., Reifert, J., Bendall, H. H., Zeller, R. W., Corbeil, J., Elliott, G., & Niemeyer, C. C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1061 · Cited by 368
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
Gumireddy, K., Reddy, M. V. R., Cosenza, S. C., Nathan, R. B., Baker, S. J., Papathi, N., Jiang, J., Holland, J., & Reddy, E. P. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.009 · Cited by 367
Elesclomol induces cancer cell apoptosis through oxidative stress
Kirshner, J. R., He, S., Balasubramanyam, V., Kepros, J., Yang, C.-Y., Zhang, M., Du, Z., Barsoum, J., & Bertin, J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0298 · Cited by 353
Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275
Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., & Sausville, E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.22.1736 · Cited by 346
In vitro three‐dimensional (3D) models in cancer research: An update
Kimlin, L. C., Casagrande, G., & Virador, V. M. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.21844 · Cited by 341
Boehm, M. F., Zhang, L., Zhi, L., McClurg, M. R., Berger, E., Wagoner, M., Mais, D. E., Suto, C. M., Davies, P. J. A., Heyman, R. A., et al. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00016a018 · Cited by 335
Munshi, N., Jeay, S., Li, Y., Chen, C.-R., France, D. S., Ashwell, M. A., Hill, J., Moussa, M. M., Leggett, D. S., & Li, C. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1173 · Cited by 326
Tozer, G. M., Prise, V. E., Wilson, J., Locke, R. J., Vojnovic, B., Stratford, M. R. L., Dennis, M. F., & Chaplin, D. J. (1999) · PubMed · Cited by 323
Hennequin, L. F., Stokes, E. S. E., Thomas, A. P., Johnstone, C., Plé, P. A., Ogilvie, D. J., Dukes, M., Wedge, S. R., Kendrew, J., & Curwen, J. O. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011022e · Cited by 311
Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
Cheng, Z., Gong, Y., Ma, Y., Lu, K., Lu, X., Pierce, L. A., Thompson, R. C., Muller, S., Knapp, S., & Wang, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3066 · Cited by 299
Wilhelm, S., & Chien, D.-S. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023393026 · Cited by 289
Can cell systems biology rescue drug discovery?
Butcher, E. C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1754 · Cited by 276
Harnessing synthetic lethal interactions in anticancer drug discovery
Chan, D. A., & Giaccia, A. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3374 · Cited by 262
The multicellular tumor spheroid model for high-throughput cancer drug discovery
LaBarbera, D. V., Reid, B. G., & Yoo, B. H. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.708334 · Cited by 255
Taylor, E. C., Kuhnt, D., Shih, C., Rinzel, S. M., Grindey, G. B., Barredo, J., Jannatipour, M., & Moran, R. G. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00101a023 · Cited by 254
Giaccone, G., Zatloukal, P., Roubec, J., Floor, K., Musil, J., Kuta, M., van Klaveren, R. J., Chaudhary, S., Gunther, A., & Shamsili, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1862 · Cited by 245
ICI 182,780, a new antioestrogen with clinical potential
Wakeling, A. E., & Bowler, J. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90204-v · Cited by 242
Development of small-molecule probes that selectively kill cells induced to express mutant RAS
Weïwer, M., Bittker, J. A., Lewis, T. A., Shimada, K., Yang, W. S., MacPherson, L., Dandapani, S., Palmer, M., Stockwell, B. R., Schreiber, S. L., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.09.047 · Cited by 237
Joo, K. M., Kim, J., Jin, J., Kim, M., Seol, H. J., Muradov, J., Yang, H., Choi, Y.-L., Park, W.-Y., Kong, D.-S., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.12.013 · Cited by 236
Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress
Shaw, A. T., Winslow, M. M., Magendantz, M., Ouyang, C., Dowdle, J., Subramanian, A., Lewis, T. A., Maglathin, R. L., Tolliday, N., & Jacks, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105941108 · Cited by 230
Rapamycin: Something Old, Something New, Sometimes Borrowed and Now Renewed
Hartford, C. M., & Ratain, M. J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100317 · Cited by 228
Podar, K., Tonon, G., Sattler, M., Tai, Y.-T., LeGouill, S., Yasui, H., Ishitsuka, K., Kumar, S., Kumar, R., Pandite, L. N., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609329103 · Cited by 216
Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
Katayama, R., Aoyama, A., Yamori, T., Qi, J., Oh-hara, T., Song, Y., Engelman, J. A., & Fujita, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3256 · Cited by 213
Gandhi, A. G., Murphy-Graham, E., Petrosino, A., Chrismer, S. S., & Weiss, C. H. (2007) · Evaluation Review · doi:10.1177/0193841x06287188 · Cited by 211
Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.
Gottardis, M. M., Bischoff, E. D., Shirley, M. A., WAGONER, M., Lamph, W. W., & Heyman, R. A. (1996) · PubMed · Cited by 199
Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy
Lee, J. A., Uhlik, M. T., Moxham, C. M., Tomandl, D., & Sall, D. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201649s · Cited by 192
Galsky, M. D., Dritselis, A., Kirkpatrick, P., & Oh, W. K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3254 · Cited by 173
Tyrosine kinase inhibitors—ZD1839 (Iressa)
Arteaga, C. L., & Johnson, D. H. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00012 · Cited by 172
Guzi, T. J., Paruch, K., Dwyer, M. P., Labroli, M., Shanahan, F., Davis, N., Taricani, L., Wiswell, D., Seghezzi, W., Penaflor, E., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0928 · Cited by 171
High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells
Caie, P. D., Walls, R. E., Ingleston-Orme, A., Daya, S., Houslay, T., Eagle, R., Roberts, M. E., & Carragher, N. O. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1148 · Cited by 171
Sorafenib: a clinical and pharmacologic review
Iyer, R., Fetterly, G., Lugade, A., & Thanavala, Y. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.496453 · Cited by 169
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
Basilico, C., Pennacchietti, S., Vigna, E., Chiriaco, C., Arena, S., Bardelli, A., Valdembri, D., Serini, G., & Michieli, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3459 · Cited by 169
Kelly, R. J., Thomas, A., Rajan, A., Chun, G., Lopez-Chavez, A., Szabo, E., Spencer, S., Carter, C. A., Guha, U., Khozin, S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt249 · Cited by 166
Chan, G. K. Y., Kleinheinz, T. L., Peterson, D., & Moffat, J. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063583 · Cited by 163
Self-citationCarson, D. A., Wasson, D. B., Esparza, L. M., Carrera, C. J., Kipps, T. J., & Cottam, H. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2970 · Cited by 158
6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): A new irreversible aromatase inhibitor
Giudici, D., Ornati, G., Briatico, G., Buzzetti, F., Lombardi, P., & di Salle, E. (1988) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(88)90129-x · Cited by 150
Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II
Hawtin, R. E., Stockett, D. E., Byl, J. A. W., McDowell, R. S., Tan, N., Arkin, M. R., Conroy, A., Yang, W., Osheroff, N., & Fox, J. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010186 · Cited by 148
Li, Q., Chen, C., Kapadia, A., Zhou, Q., Harper, M. K., Schaack, J. B., & LaBarbera, D. V. (2011) · SLAS DISCOVERY · doi:10.1177/1087057110392995 · Cited by 146
Treat cancers by targeting survivin: Just a dream or future reality?
Coumar, M. S., Tsai, F.-Y., Kanwar, J. R., Sarvagalla, S., & Cheung, C. H. A. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.02.002 · Cited by 145
Harringtonine, an Inhibitor of Initiation of Protein Biosynthesis
Huang, M. (1975) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10662-7 · Cited by 144
Urdiales, J. L., Morata, P., de Castro, I. N., & Sánchez‐Jiménez, F. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04151-1 · Cited by 142
Lewis, K. D., Samlowski, W. E., Ward, J. F., Catlett, J., Cranmer, L. D., Kirkwood, J. M., Lawson, D. H., Whitman, E. J., & Gonzalez, R. C. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9333-6 · Cited by 141
Arrowsmith, J. E. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3630 · Cited by 140
Drewitz, M., Helbling, M. M., Fried, N., Bieri, M., Moritz, W., Lichtenberg, J., & Kelm, J. M. (2011) · Biotechnology Journal · doi:10.1002/biot.201100290 · Cited by 137
Personalizing Oncology: Perspectives and Prospects
Mendelsohn, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3605 · Cited by 137
Screening for Cell Migration Inhibitors via Automated Microscopy Reveals a Rho-Kinase Inhibitor
Yarrow, J. C., Totsukawa, G., Charras, G., & Mitchison, T. J. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.01.015 · Cited by 137
Bax, D. A., Little, S. E., Gaspar, N., Perryman, L., Marshall, L. V., Viana‐Pereira, M., Jones, T. A., Williams, R. D., Grigoriadis, A. E., Vassal, G., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005209 · Cited by 137
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient
Wiman, K. G. (2010) · Oncogene · doi:10.1038/onc.2010.188 · Cited by 134
Wong, H., Choo, E. F., Alicke, B., Ding, X., La, H., McNamara, E., Theil, F.-P., Tibbitts, J., Friedman, L. S., Hop, C. E. C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0738 · Cited by 133
Hsiao, A. Y., Tung, Y.-C., Kuo, C.-H., Mosadegh, B., Bedenis, R., Pienta, K. J., & Takayama, S. (2012) · Biomedical Microdevices · doi:10.1007/s10544-011-9608-5 · Cited by 129
Jimeno, A., Li, J., Messersmith, W. A., Laheru, D. A., Rudek, M. A., Maniar, M. L., Hidalgo, M. M., Baker, S. D., & Donehower, R. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9788 · Cited by 128
Jiang, P., Mukthavavam, R., Chao, Y. S., Bharati, I. S., Fogal, V., Pastorino, S., Cong, X., Nomura, N., Gallagher, M., Abbasi, T., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-13 · Cited by 125
Preclinical discovery of ixabepilone, a highly active antineoplastic agent
Lee, F. Y., Borzilleri, R. M., Fairchild, C. R., Kamath, A. V., Smykla, R. A., Kramer, R. A., & Vite, G. D. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0724-8 · Cited by 121
Drug discovery in the next decade: innovation needed ASAP
Bennani, Y. L. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.004 · Cited by 120
Kim, M., Nam, H.-J., Kim, H., Han, S., Im, S., Kim, T., Oh, D., & Bang, Y. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.010 · Cited by 118
Isaacs, J. T., Antony, L., Dalrymple, S. L., Brennen, W. N., Gerber, S., Hammers, H., Wissing, M., Kachhap, S., Luo, J., Xing, L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2730 · Cited by 116
Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy
Shortt, J., Hsu, A. K., & Johnstone, R. W. (2013) · Oncogene · doi:10.1038/onc.2012.599 · Cited by 112
Finding the tumor copycat: Therapy fails, patients don’t
Ellis, L. M., & Fidler, I. J. (2010) · Nature Medicine · doi:10.1038/nm0910-974 · Cited by 109
Hayakawa, F., Sugimoto, K., Harada, Y., Hashimoto, N., Ohi, N., Kurahashi, S., & Naoe, T. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.63 · Cited by 108
Vidal, A., Muñoz, C., Guillén, M.-J., Moretó, J., Puertas, S., Martínez‐Iniesta, M., Figueras, A., Padullés, L., García-Rodríguez, F. J., Berdiel‐Acer, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1513 · Cited by 108
A Cell-Based High-Content Screening Assay Reveals Activators and Inhibitors of Cancer Cell Invasion
Quintavalle, M., Elia, L., Price, J. H., Heynen‐Genel, S., & Courtneidge, S. A. (2011) · Science Signaling · doi:10.1126/scisignal.2002032 · Cited by 107
Chapman, C. M., Sun, E. X., Roschewski, M. J., Aue, G., Farooqui, M., Stennett, L. S., Gibellini, F., Arthur, D. C., Pérez‐Galán, P., & Wiestner, A. U. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2113 · Cited by 106
Funahashi, Y., Sugi, N. H., Semba, T., Yamamoto, Y., Hamaoka, S., Tsukahara-Tamai, N., Ozawa, Y., Tsuruoka, A., Nara, K., Takahashi, K., et al. (2002) · PubMed · Cited by 103
Gandhi, V. V., Plunkett, W. K., Rodriguez, C. O., Nowak, B. J., Du, M., Ayres, M., Kisor, D. F., Mitchell, B. S., Kurtzberg, J., & Keating, M. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3607 · Cited by 103
Reddy, M. V. R., Venkatapuram, P., Mallireddigari, M. R., Pallela, V. R., Cosenza, S. C., Robell, K. A., Akula, B., Hoffman, B. S., & Reddy, E. P. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200570p · Cited by 97
Sams‐Dodd, F. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.010 · Cited by 97
The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response
Glaros, T., Stockwin, L. H., Mullendore, M. E., Smith, B., Morrison, B. L., & Newton, D. L. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1868-0 · Cited by 94
Dvořáková, K., Payne, C. M., Tome, M. E., Briehl, M. M., McClure, T. D., & Dorr, R. T. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00380-4 · Cited by 89
Zhang, Y., Guessous, F., Kofman, A., Schiff, D., & Abounader, R. (2010) · PubMed · Cited by 88
Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery
Li, H., Zhou, H., Wang, D., Qiu, J., Zhou, Y., Li, X., Rosenfeld, M. G., Ding, S., & Fu, X. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200305109 · Cited by 86
Wong, H. H., Vernillet, L., Peterson, A., Ware, J. A., Lee, L., Martini, J., Yu, P., Li, C., Rosario, G. D., Choo, E. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0445 · Cited by 81
Discovery and preclinical development of vismodegib
Gould, S. E., Low, J. A., Marsters, J. C., Robarge, K. D., Rubin, L. L., de Sauvage, F. J., Sutherlin, D. P., Wong, H. H., & Yauch, R. L. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.920816 · Cited by 74
From triazines and triazenes to temozolomide
Stevens, M. F. G., & Newlands, E. S. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80221-7 · Cited by 74
Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells
Prasad, A., Park, I.-W., Allen, H. E., Zhang, X., Reddy, M. V. R., Boominathan, R., Reddy, E. P., & Groopman, J. E. (2009) · Oncogene · doi:10.1038/onc.2008.502 · Cited by 73
The Contribution of Mechanistic Understanding to Phenotypic Screening for First-in-Class Medicines
Swinney, D. C. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113501199 · Cited by 71
McLaughlin, J. R., Markovtsov, V. V., Li, H., Wong, S., Gelman, M. S., Zhu, Y., Franci, C., Lang, D. W., Pali, E. S., Lasaga, J., et al. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0641-1 · Cited by 70
Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis
Vitucci, M., Karpinich, N. O., Bash, R. E., Werneke, A. M., Schmid, R. S., White, K. K., McNeill, R. S., Huff, B., Wang, S., Dyke, T. V., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not084 · Cited by 69
Yoshida, T., Kakegawa, J., Yamaguchi, T., Hantani, Y., Okajima, N., Sakai, T., Watanabe, Y., & Nakamura, M. (2012) · Oncotarget · doi:10.18632/oncotarget.747 · Cited by 67
Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumors
Adjei, A. A. (2000) · Annals of Oncology · doi:10.1023/a:1008379101017 · Cited by 65
Giuliani, F. C., & Kaplan, N. O. (1980) · PubMed · Cited by 65
Developmental pathways in breast cancer and breast tumor-initiating cells: Therapeutic implications
Izrailit, J., & Reedijk, M. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.11.028 · Cited by 64
Identification of JTP‐70902, a p15INK4b‐inductive compound, as a novel MEK1/2 inhibitor
Yamaguchi, T., Yoshida, T., Kurachi, R., Kakegawa, J., Hori, Y., Nanayama, T., Hayakawa, K., Abe, H., Takagi, K., Matsuzaki, Y., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00604.x · Cited by 63
YAN, H. H., Chen, X., Zhang, Q., Qin, J., Li, H., Liu, C., Calhoun‐Davis, T., Coletta, L. D., Klostergaard, J., Fokt, I., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024397 · Cited by 57
Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma
Lee, T. K., Cheung, V. C. H., & Ng, I. O. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.05.001 · Cited by 57
Mangana, J., Levesque, M. P., Karpova, M. B., & Dummer, R. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.665872 · Cited by 56
Engström, P. G., Tommei, D., Stricker, S. H., Ender, C., Pollard, S. M., & Bertone, P. (2012) · Genome Medicine · doi:10.1186/gm377 · Cited by 53
WASHBURN, S. L. (1967) · American Journal of Physical Anthropology · doi:10.1002/ajpa.1330270309 · Cited by 51
Sha, S.-K., Sato, T., Kobayashi, H., Ishigaki, M., Yamamoto, S., Sato, H., Takada, A., Nakajyo, S., Mochizuki, Y., Friedman, J. M., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0371 · Cited by 51
Gandhi, V. V., Keating, M. J., Bate, G., & Kirkpatrick, P. N. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1933 · Cited by 49
Isaacs, J. T. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.514262 · Cited by 47
Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy
Joshi, A. D., Loilome, W., Siu, I., Tyler, B., Gallia, G. L., & Riggins, G. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044372 · Cited by 46
Robarge, K. D., Brunton, S. A., Castanedo, G. M., Cui, Y., Dina, M. S., Goldsmith, R. A., Gould, S. E., Guichert, O., Gunzner, J. L., Halladay, J. S., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.129 · Cited by 44
Tivantinib—a cytotoxic drug in MET inhibitor's clothes?
Michieli, P., & Nicolantonio, F. D. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.86 · Cited by 41
Haglund, C., Åleskog, A., Nygren, P., Gullbo, J., Höglund, M., Wickström, M., Larsson, R. L., & Lindhagen, E. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1746-1 · Cited by 41
Discontinued drugs in 2012: oncology drugs
Williams, R. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.847088 · Cited by 41
From Anecdote to Targeted Therapy: The Curious Case of Thalidomide in Multiple Myeloma
Licht, J. D., Shortt, J., & Johnstone, R. W. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.019 · Cited by 38
Stoops, S. L., Pearson, A. S., Weaver, C., Waterson, A. G., Days, E., Farmer, C., Brady, S. C., Weaver, C. D., Beauchamp, R. D., & Lindsley, C. W. (2011) · ACS Chemical Biology · doi:10.1021/cb100305h · Cited by 38
Guirouilh‐Barbat, J., Antony, S., & Pommier, Y. G. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0336 · Cited by 36
Roller, D. G., Axelrod, M. J., Capaldo, B. J., Jensen, K., Mackey, A. J., Weber, M. J., & Gioeli, D. G. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0461 · Cited by 36
Lung cancer-initiating cells: a novel target for cancer therapy
Morrison, B. J., Morris, J. C., & Steel, J. C. (2013) · Targeted Oncology · doi:10.1007/s11523-012-0247-4 · Cited by 31
Phenotypic High-Throughput Screening Elucidates Target Pathway in Breast Cancer Stem Cell–Like Cells
Carmody, L., Germain, A. R., VerPlank, L., Nag, P. P., Muñoz, B., Perez, J. R., & Palmer, M. A. J. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112458317 · Cited by 30
Drug candidates derailed in case of mistaken identity
Ledford, H. K. (2012) · Nature · doi:10.1038/483519a · Cited by 28
Azacitidine and the beginnings of therapeutic epigenetic modulation
O’Dwyer, K. M., & Maslak, P. G. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.11.1981 · Cited by 28
Misund, K., Baranowska, K. A., Holien, T., Rampa, C., Klein, D. C. G., Børset, M., Waage, A., & Sundan, A. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113478168 · Cited by 23
Dabrafenib in the treatment of advanced melanoma
Medina, T. M., Amaria, M. N., & Jimeno, A. (2013) · Drugs of today · doi:10.1358/dot.2013.49.6.1968669 · Cited by 22
Discovery of Novel Proteasome Inhibitors Using a High-Content Cell-Based Screening System
Lavelin, I., Beer, A., Kam, Z., Rotter, V., Oren, M., Navon, A., & Geiger, B. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008503 · Cited by 21
Roschewski, M. J., Farooqui, M., Aue, G., Wilhelm, F. E., & Wiestner, A. U. (2013) · Leukemia · doi:10.1038/leu.2013.79 · Cited by 21
Phenotypic Fingerprinting of Small Molecule Cell Cycle Kinase Inhibitors for Drug Discovery
Low, J. A., Chakravartty, A., Blosser, W. D., Dowless, M. S., Chalfant, C., Bragger, P., & Stancato, L. F. (2009) · Current Chemical Genomics · doi:10.2174/1875397300903010013 · Cited by 21
Lee, G., Shim, J., Cho, B., Jung, J., Lee, D.-S., & Oh, I. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0734-2 · Cited by 20
Mulji, A., Haslam, C. P., Brown, F., Randle, R. A., Karamshi, B., Smith, J. E., Eagle, R., Muñoz, J. A., Taylor, J., Sheikh, A., et al. (2012) · SLAS DISCOVERY · doi:10.1177/1087057111418229 · Cited by 20
Danovi, D., Folarin, A., Baranowski, B., & Pollard, S. M. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-391856-7.00040-8 · Cited by 19
Qian, J., Lü, L., Wu, J., & Ma, H. (2013) · Assay and Drug Development Technologies · doi:10.1089/adt.2013.515 · Cited by 16
Hwang, S. G., Park, J., Park, J. Y., Park, C. H., Lee, K.-H., Cho, J. W., Hwang, J., & Seong, J. Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044259 · Cited by 14
Cancer-Initiating Enriched Cell Lines from Human Glioblastoma: Preparing for Drug Discovery Assays
Romaguera-Ros, M., Peris‐Celda, M., Cruz, J. O. L., Carrión-Navarro, J., Pérez‐García, A., García‐Verdugo, J. M., & Ayuso‐Sacido, Á. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9283-1 · Cited by 13
Sahasrabudhe, S. R., Lai, S., Pierce, M. M., Clemens, C. M., Venkat, R. G., Rebentisch, M., Senina, A. V., Becklin, R. R., Richards, S. K., Erkkila, T. H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.14586 · Cited by 8
A small molecule inhibitor of α4 integrin-dependent cell migration
Lee, J., Hong, J., Nam, T., Peters, E. C., Orth, A. P., Geierstanger, B. H., Goldfinger, L. E., Ginsberg, M. H., Cho, C. Y., & Schultz, P. G. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.02.067 · Cited by 7
New tricks from an old drug: A role for quinacrine in anti-cancer therapy?
Chau, C. H., & Figg, W. D. (2009) · Cell Cycle · doi:10.4161/cc.8.24.10473 · Cited by 3
Carter, S. K. (1972) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12625903 · Cited by 3
BAL27862: A Unique Microtubule Destabilizer Active Against Chemorefractory Breast Cancers.
Breuleux, M., Bachmann, F., Pohlmann, J., Mathews, S., Burger, K., Kellenberger, L., & Lane, H. A. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-2093 · Cited by 2
Cited by
Natural products as sources of new drugs from 1981 to 2014
Newman, D. J., & Cragg, G. M. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01055 · Cited by 5,858
Natural product discovery: past, present, and future
Katz, L., & Baltz, R. H. (2016) · Journal of Industrial Microbiology and Biotechnology · doi:10.1007/s10295-015-1723-5 · Cited by 1,144
“Both target-based and phenotypic screening are too vast to be described comprehensively here, but are covered in a number of reviews [74, 81, 102, 118].”
BackgroundBray, M.-A., Singh, S., Han, H., Davis, C. T., Borgeson, B., Hartland, C., Kost-Alimova, M., Gustafsdottir, S. M., Gibson, C. C., & Carpenter, A. E. (2016) · Nature Protocols · doi:10.1038/nprot.2016.105 · Cited by 1,090
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Self-citationMetallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Metadata
- Authors
- Moffat, J. G., Rudolph, J., & Bailey, D.
- Affiliations
- Genentech (US)
- Corresponding author
- Moffat, John G.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-07-18
- Volume
- 13
- Issue
- 8
- Pages
- 588-602
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2123059506
- Semantic Scholar
- 1042a4c884176fac046b7c6751c953ed949f8066
- Cited by
- 507
- References
- 182
- Citations by year
- 2026: 28 · 2025: 37 · 2024: 43 · 2023: 30 · 2022: 36 · 2021: 48 · 2020: 45 · 2019: 48 · 2018: 52 · 2017: 56 · 2016: 42 · 2015: 39 · 2014: 3
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Food and Drug Administration
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- phenotypic screening, anticancer drug discovery, anticancer drug development, small molecule anticancer agents, FDA-approved anticancer drugs, target-based drug discovery, cytotoxicity, mitotic arrest
- MeSH terms
- Antineoplastic Agents, Drug Screening Assays, Antitumor, Forecasting, Humans, Neoplasms, Phenotype, History, 20th Century, History, 21st Century, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.